NK1 receptor antagonists under investigation for the treatment of affective disorders

Expert Opinion on Investigational Drugs

Volumn 15, Issue 5, 2006, Pages 479-486

  Czéh, Boldizsár ^a,b   Fuchs, Eberhard ^a,b,c   Simon, Mária ^a,d  

^a GERMAN PRIMATE CENTER   (Germany)

^b Deutsche Forschungsgemeinschaft   (Germany)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Antidepressant; Anxiety; Mood disorders; Neurokinin 1 receptor; Substance P

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 2 BENZYL 1 (3,5 DIMETHYLBENZOYL) 4 (4 QUINOLINYLMETHYLAMINO)PIPERIDINE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 5 [[2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 MORPHOLINYL]METHYL] N,N DIMETHYL 1H 1,2,3 TRIAZOLE 4 METHANAMINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; APREPITANT; BEFETUPITANT; BENZODIAZEPINE DERIVATIVE; CASOPITANT; CITALOPRAM; CJ 17493; FLUOXETINE; FLUVOXAMINE; GW 823296; L 759274; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; NEUROKININ 3 RECEPTOR; NKP 608; PAROXETINE; R 673; RO 675930; SLV 323; SSR 240600; SUBSTANCE P; TAK 637; UNCLASSIFIED DRUG; UNINDEXED DRUG; VESTIPITANT; VOFOPITANT; NEW DRUG;

ANXIETY DISORDER; ASTHENIA; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; HUMAN; MOOD DISORDER; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PROTEIN EXPRESSION; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SOMNOLENCE; TRANQUILIZING ACTIVITY; ANIMAL; DRUG ANTAGONISM; METABOLISM; PSYCHOLOGICAL ASPECT;

ANIMALS; DRUGS, INVESTIGATIONAL; HUMANS; MOOD DISORDERS; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 33646464377     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.5.479     Document Type: Review

References (65)

1. FARVOLDEN P, KENNEDY SH, LAM RW: Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future. Expert Opin. Investig. Drugs (2003) 12(1):65-86.
2. VON EULER US, GADDUM JH: An unidentified depressor substance in certain tissue extracts. J. Physiol. (Lond.) (1931) 72:74-87.
3. CHANG MM, LEEMAN SE, NIALL HD: Amino-acid sequence of substance P. Nat. New Biol. (1971) 232(29):86-87.
4. 1) receptor predominates in human brain. J. Comp. Neurol. (2005) 490(4):335-353.
5. DE FELIPE C, HERRERO JF, O'BRIEN JA et al.: Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature (1998) 392(6674):394-397.
6. 1 receptor have a role in depression and anxiety? Curr. Pharm. Des. (2005) 11(12):1529-1547.
7. HERPFER I, LIEB K: Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. CNS Drugs (2005) 19(4):275-293.
8. 1 receptor. J. Clin. Psychiatry (2002) 63(Suppl. 11):6-10.
9. KANEKO T, SHIGEMOTO R, NAKANISHI S, MIZUNO N: Morphological and chemical characteristics of substance P receptor-immunoreactive neurons in the rat neocortex. Neuroscience (1994) 60(1):199-211
10. ACSADY L, KATONA I, GULYAS AI, SHIGEMOTO R, FREUND TF: Immunostaining for substance P receptor labels GABAergic cells with distinct termination patterns in the hippocampus. J. Comp. Neurol. (1997) 378(3):320-336.
11. MAUBACH KA, MARTIN K, SMITH DW et al.: Substance P stimulates inhibitory synaptic transmission in the guinea pig basolateral amygdala in vitro. Neuropharmacology (2001) 40(6):806-817.
12. STACEY AE, WOODHALL GL, JONES RS: Activation of neurokinin-1 receptors promotes GABA release at synapses in the rat entorhinal cortex. Neuroscience (2002) 115(2):575-586.
13. OGIER R, RAGGENBASS M: Action of tachykinins in the rat hippocampus: modulation of inhibitory synaptic transmission. Eur. J. Neurosci. (2003) 17(12):2639-2647.
14. 1) antagonist. Neuropsychopharmacology (2005) 30(1):67-79.
15. SANTARELLI L, GOBBI G, DEBS PC et al.: Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc. Natl. Acad. Sci. USA (2001) 98(4):1912-1917.
16. 1) in the locus coeruleus complex: a double immunofluorescence study in the rat. Brain Res. (2000) 873(1):155-159.
17. GUIARD BP, FROGER N, HAMON M, GARDIER AM, LANFUMEY L: Sustained pharmacological blockade of NK substance P receptors causes functional desensitization of dorsal raphe 5-HT autoreceptors in mice. J. Neurochem. (2005) 95(6):1713-1723.
18. CONLEY RK, CUMBERBATCH MJ, MASON GS et al.: Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J. Neurosci. (2002) 22(17):7730-7736.
19. GOBBI G, BLIER P: Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides (2005) 26(8):1383-1393.
20. KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 281(5383):1640-1645.
21. 1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. J. Neurochem. (2001) 76(6):1949-1954.
22. GUIARD BP, PRZYBYLSKI C, GUILLOUX JP et al.: Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J. Neurochem. (2004) 89(1):54-63.
23. 1) receptor antagonist, on the response in the forced swim test and on monoamine extracellular levels in the frontal cortex of the mouse. Neurosi. Lett. (2003) 345(2):73-76.
24. LIEB K, FIEBICH BL, HERPFER I, MANTOVANI M, LOFFLER M, FEUERSTEIN TJ: No modulatory effect of neurokinin-1 receptor antagonists on serotonin uptake in human and rat brain synaptosomes. Eur. Neuropsychopharmacol. (2005) 15(6):641-646.
25. DAVID DJ, FROGER N, GUIARD B et al.: Serotonin transporter in substance P (neurokinin 1) receptor knock-out mice. Eur. J. Pharmacol. (2004) 492(1):41-48.
26. VALENTINO RJ, BEY V, PERNAR L, COMMONS KG: Substance P acts through local circuits within the rat dorsal raphe nucleus to alter serotonergic neuronal activity. J. Neurosci. (2003) 23(18):7155-7159.
27. BLIER P, GOBBI G, HADDJERI N, SANTARELLI L, MATHEW G, HEN R: Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response. J. Psychiatry Neurosci. (2004) 29(3):208-218.
28. 1) in the living human brain using positron emission tomography. J. Clin. Psychiatry (2002) 63(Suppl. 11):18-24.
29. BERGSTROM M, HARGREAVES RJ, BURNS HD et al.: Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol. Psychiatry (2004) 55(10):1007-1012.
30. 18F]SPA-RQ). Mol. Imaging Biol. (2004) 6(6):373-384.
31. FURMARK T, APPEL L, MICHELGARD A et al.: Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol. Psychiatry (2005) 58(2):132-142.
32. CARLSON PJ, SINGH JB, ZARATE CA Jr, DREVETS WC, MANJI HK: Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 3(1):22-41.
33. MANJI HK, DREVETS WC, CHARNEY DS: The cellular neurobiology of depression. Nat. Med. (2001) 7(5):541-547.
34. MANJI HK, QUIROZ JA, SPORN J et al.: Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry (2003) 53(8):707-742.
35. CAMPBELL S, MARRIOTT M, NAHMIAS C, MacQUEEN GM: Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am. J. Psychiatry (2004) 161(4):598-607.
36. RAJKOWSKA G: Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol. Psychiatry (2000) 48(8):766-777.
37. McEWEN BS: The neurobiology of stress: from serendipity to clinical relevance. Brain Res. (2000) 886(1-2):172-189.
38. GROSS CG: Neurogenesis in the adult brain: death of a dogma. Nat. Rev. Neurosci. (2000) 1(1):67-73.
39. EISCH AJ: Adult neurogenesis: implications for psychiatry. Prog. Brain Res. (2002) 138:315-342.
40. CZEH B, MICHAELIS T, WATANABE T et al.: Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. Proc. Natl. Acad. Sci. USA (2001) 98(22):12796-12801.
41. MALBERG JE, DUMAN RS: Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology (2003) 28(9):1562-1571.
42. FUCHS E, CZEH B, FLUGGE G: Examining novel concepts of the pathophysiology of depression in the chronic psychosocial stress paradigm in tree shrews. Behav. Pharmacol. (2004) 15(5-6):315-325.
43. DUMAN RS: Depression: a case of neuronal life and death? Biol. Psychiatry (2004) 56(3):140-145.
44. REIF A, FRITZEN S, FINGER M et al.: Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol. Psychiatry (2006) (In Press).
45. HENN FA, VOLLMAYR B: Neurogenesis and depression: etiology or epiphenomenon? Biol. Psychiatry (2004) 56(3):146-150.
46. SANTARELLI L, SAXE M, GROSS C et al.: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science (2003) 301(5634):805-809.
47. VAN DER HART MG, CZEH B, DE BIURRUN G et al.: Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume. Mol. Psychiatry (2002) 7(9):933-941.
48. 1 receptor antagonist, in a chronic psychosocial stress model for depression. Pychopharmacology (Berl.) (2005) 180(3):548-557.
49. MORCUENDE S, GADD CA, PETERS M et al.: Increased neurogenesis and brain-derived neurotrophic factor in neurokinin-1 receptor gene knockout mice. Eur. J. Neurosci. (2003) 18(7):1828-1836.
50. MALBERG JE, EISCH AJ, NESTLER EJ, DUMAN RS: Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci. (2000) 20(24):9104-9110.
51. GERACIOTI TD, CARPENTER LL, OWENS MJ et al.: Elevated cerebrospinal fluid substance P concentrations in posttraumatic stress disorder and major depression. Am. J. Psychiatry (2006) 163:637-643.
52. LIEB K, AHLVERS K, DANCKER K et al.: Effects of the neuropeptide substance P on sleep, mood, and neuroendocrine measures in healthy young men. Neuropsychopharmacology (2002) 27(6):1041-1049.
53. BONDY B, BAGHAI TC, MINOV C et al.: Substance P serum levels are increased in major depression: preliminary results. Biol. Psychiatry (2003) 53(6):538-542.
54. LIEB K, WALDEN J, GRUNZE H, FIEBICH BL, BERGER M, NORMANN C: Serum levels of substance P and response to antidepressant pharmacotherapy. Pharmacopsychiatry (2004) 37(5):238-239.
55. DEUSCHLE M, SANDER P, HERPFER I, FIEBICH BL, HEUSER I, LIEB K: Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment. Psychiatry Res. (2005) 136(1):1-6.
56. 1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia. Biol. Psychiatry (2000) 47(1):80-83.
57. STOCKMEIER CA, SHI X, KONICK L et al.: Neurokinin-1 receptors are decreased in major depressive disorder. Neuroreport (2002) 13(9):1223-1227.
58. 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. Eur. J. Neurosci. (2005) 21(6):1712-1718.
59. 1) antagonists. Trends Pharmacol. Sci. (1999) 20(12):485-490.
60. ENSERINK M: Can the placebo be the cure? Science (1999) 284(5412):238-240.
61. KRAMER MS: Clinical update: substance P antagonists in patients with major depression. Eur. Psychiatry (2002) 17(Suppl. 1):S10-S10.
62. 1) receptor antagonist in major depression. Neuropsychopharmacology (2004) 29(2):385-392.
63. KELLER M, MONTGOMERY S, BALL W et al.: Lack of efficacy of the substance P (neurokinin 1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol. Psychiatry (2006) 59(3):216-223.
64. 1-receptor antagonist. Expert. Opin. Pharmacother. (2003) 4(12):2279-2296.
65. CHAPPEL P: Effects of CP-122721, a selective NK-1 receptor antagonist, in patients with MDD. 42nd Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton, USA (12 June 2002).